Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1113.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.48M.
Undervalued
The company’s latest PE is -4.42, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.76M shares, increasing 8.04% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 94.56K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.09.